Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration ...

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

The country has recorded a surge of hepatitis cases, and the alarming situation has called for better clarity in ...

A viral reel by a Mumbai-based doctor claims that threading a common beauty procedure can increase one’s risk of hepatitis B infection Here’s what our expert has to say ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

Learn about 5 liver infections that can hide in your body for decades without symptoms. Discover warning signs and prevention ...

hepatitis C and hepatitis D usually cause chronic disease, liver cancer and cirrhosis, whereas hepatitis A and hepatitis E cause acute disease but may lead to more serious complications in certain ...

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...